Company

Apellis

Rocket Ship Rating

Rocket Ship Rating: 90 out of 100

Leading the way in complement science for patients

Also known as Apellis Pharmaceuticals, Inc.

Biotech & therapeutics
Care delivery & digital health
Health IT

Status: Operatingas of 2026-09-18
Business model: B2B
Headquarters: Cambridge, MA, United States
Legal name: Apellis Pharmaceuticals, Inc.

Open relationship map

Claim, correct or request removal

Record updated 28 September 2026

About

We aim to transform treatment across a broad range of debilitating diseases driven by complement

Funding snapshot

Total raised: $140MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
Latest round: Round, $20M2017-08-07

Funding rounds

Round, 2017: $20M2017-08-07, SEC form D sold, 16 investors
Round, 2015: $32.1M2015-12-24, SEC form D sold, 6 investors
Round, 2015: $47.1M2015-12-24, SEC form D sold, 7 investors
Round, 2014: $17.7M2014-12-05, SEC form D sold, 1 investor
Round, 2013: $17.8M2013-07-30, SEC form D sold, 25 investors
Round, 2012: $693K2012-07-18, SEC form D sold, 9 investors
Round, 2011: $3M2011-05-20, SEC form D sold, 15 investors
Round, 2010: $1.7M2010-05-21, SEC form D sold, 6 investors